Andrographis paniculata extract

Abstract

An extract of Andrographis paniculata extract containing andrographolide, 14-deoxyandrographolide, 14-deoxy-11,12-dehydroandrographotide, neoandrographolide, polysacchorides, and flavanoids. Also disclosed is a pharmaceutical composition containing such an extract and its use for treating inflammatory bowel disease.

1 - 25 . (canceled) 
     
     
         26 . A solid dosage form for oral administration to a human to treat an inflammatory bowel disease, comprising:
 (1) an extract of Andrographis paniculata comprising andrographolide lactones:
 wherein said andrographolide lactones comprise:
 andrographolide in an amount ranging from 2% to 20% of the dry weight of the extract; 
 14-deoxyandrographolide in an amount ranging from greater than 0 to 2% of the dry weight of the extract; 
 14-deoxy-11,12-dehydrogen-andrographolide in an amount ranging from 1% to 6% of the dry weight of the extract; and 
 neoandrographolide in an amount ranging from 1% to 5% of the dry weight of the extract, and 
 
   (2) wherein said solid dosage form, following said oral administration to said human, shows efficacy in treating said inflammatory bowel disease, and wherein said solid dosage form further comprises at least one pharmaceutically acceptable carrier.   
     
     
         27 . The solid dosage form of  claim 26 , wherein said extract further comprises polysaccharides and flavonoids. 
     
     
         28 . The solid dosage form of  claim 26 , further comprising dextrin. 
     
     
         29 . A solid dosage form for oral administration to a human to treat ulcerative colitis, comprising:
 (1) an extract of  Andrographis paniculata  comprising andrographolide lactones:
 wherein said andrographolide lactones comprise:
 andrographolide in an amount ranging from 2% to 20% of the dry weight of the extract; 
 14-deoxyandrographolide in an amount ranging from greater than 0 to 2% of the dry weight of the extract; 
 14-deoxy-11,12-dehydrogen-andrographolide in an amount ranging from 1% to 6% of the dry weight of the extract; and 
 neoandrographolide in an amount ranging from 1 to 5% of the dry weight of the extract, and 
 
   (2) wherein said solid dosage form, following oral administration to said human, shows efficacy in treating said ulcerative colitis, and wherein said solid dosage form further comprises at least one pharmaceutically acceptable carrier.   
     
     
         30 . The solid dosage form of  claim 29 , wherein said extract further comprises polysaccharides and flavonoids. 
     
     
         31 . The solid dosage form of  claim 29 , further comprising dextrin.